{
    "cc8420fe-01f8-3e0b-85b4-85ff830fff37": {
        "uuid": "cc8420fe-01f8-3e0b-85b4-85ff830fff37",
        "title": "Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?",
        "publisher": "Investor's Business Daily",
        "link": "https://finance.yahoo.com/m/cc8420fe-01f8-3e0b-85b4-85ff830fff37/is-abbvie-stock-a-buy-as.html",
        "providerPublishTime": 1654277955,
        "type": "STORY"
    },
    "3483b764-2b44-37ad-bdef-66b9a54121c2": {
        "uuid": "3483b764-2b44-37ad-bdef-66b9a54121c2",
        "title": "Analyst Report: AbbVie Inc.",
        "publisher": "Morningstar Research",
        "link": "https://finance.yahoo.com/m/3483b764-2b44-37ad-bdef-66b9a54121c2/analyst-report%3A-abbvie-inc..html",
        "providerPublishTime": 1654275254,
        "type": "STORY"
    },
    "fd7e2f8d-1006-373b-9f7c-ae2009be77cb": {
        "uuid": "fd7e2f8d-1006-373b-9f7c-ae2009be77cb",
        "title": "3 Reasons to Buy This Blue-Chip Stock",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/fd7e2f8d-1006-373b-9f7c-ae2009be77cb/3-reasons-to-buy-this.html",
        "providerPublishTime": 1654271100,
        "type": "STORY"
    },
    "58a7cb52-47a7-326e-8122-c750fc458ab4": {
        "uuid": "58a7cb52-47a7-326e-8122-c750fc458ab4",
        "title": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/abbvie-inc-abbv-trending-stock-130001232.html",
        "providerPublishTime": 1654261201,
        "type": "STORY"
    },
    "afe67693-c378-342f-83ed-48ea80078215": {
        "uuid": "afe67693-c378-342f-83ed-48ea80078215",
        "title": "J&J, AbbVie cancer drug significantly slows progression of rare lymphoma -study",
        "publisher": "Reuters",
        "link": "https://finance.yahoo.com/news/j-j-abbvie-cancer-drug-120000043.html",
        "providerPublishTime": 1654257600,
        "type": "STORY"
    },
    "b03d7171-e8a4-3f43-a78f-268d397b2f8c": {
        "uuid": "b03d7171-e8a4-3f43-a78f-268d397b2f8c",
        "title": "1 Green Flag for AbbVie in 2022 and 1 Red Flag",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/b03d7171-e8a4-3f43-a78f-268d397b2f8c/1-green-flag-for-abbvie-in.html",
        "providerPublishTime": 1654096500,
        "type": "STORY"
    },
    "2ac74487-ad2a-3678-a415-7f5abf810b9a": {
        "uuid": "2ac74487-ad2a-3678-a415-7f5abf810b9a",
        "title": "AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ\u00ae) in Patients with Axial Spondyloarthritis at EULAR 2022",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/abbvie-presents-positive-results-phase-143500109.html",
        "providerPublishTime": 1654094100,
        "type": "STORY"
    },
    "4fe0d19e-43f6-3188-9caa-3d697d740d6c": {
        "uuid": "4fe0d19e-43f6-3188-9caa-3d697d740d6c",
        "title": "My 3 Favorite Dividend Stocks to Buy in June",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/4fe0d19e-43f6-3188-9caa-3d697d740d6c/my-3-favorite-dividend-stocks.html",
        "providerPublishTime": 1654077120,
        "type": "STORY"
    }
}